AR108781A1 - Aumento de la inmunogenicidad del péptido l2 de virus de papiloma humano (hpv) - Google Patents

Aumento de la inmunogenicidad del péptido l2 de virus de papiloma humano (hpv)

Info

Publication number
AR108781A1
AR108781A1 ARP170101558A ARP170101558A AR108781A1 AR 108781 A1 AR108781 A1 AR 108781A1 AR P170101558 A ARP170101558 A AR P170101558A AR P170101558 A ARP170101558 A AR P170101558A AR 108781 A1 AR108781 A1 AR 108781A1
Authority
AR
Argentina
Prior art keywords
hpv
immunogenic polypeptide
immunogenicity
peptide
increase
Prior art date
Application number
ARP170101558A
Other languages
English (en)
Inventor
Gloria Spagnoli
Somayeh Pouyanfard
Simone Ottonello
Martin MLLER
Angelo Bolchi
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Publication of AR108781A1 publication Critical patent/AR108781A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación refiere a un polipéptido inmunogénico que comprende una pluralidad de péptidos N-terminales de L2 de virus de papiloma humano (HPV) que corresponden a los aminoácidos 20 a 50 del polipéptido L2 de HPV16, en donde dichos péptidos N-terminales de L2 de HPV son péptidos N-terminales de L2 de al menos dos genotipos diferentes de HPV. También se relaciona con dicho polipéptido inmunogénico para su uso en medicina y para su uso en la vacunación contra la infección por HPV. Además, la presente acta se relaciona con un polinucleótido que codifica el polipéptido inmunogénico y con una célula hospedadora que comprende el mismo. Además, la divulgación se refiere a kits, métodos, y usos relacionados al polipéptido inmunogénico de la presente acta.
ARP170101558A 2016-06-07 2017-06-07 Aumento de la inmunogenicidad del péptido l2 de virus de papiloma humano (hpv) AR108781A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16173313 2016-06-07

Publications (1)

Publication Number Publication Date
AR108781A1 true AR108781A1 (es) 2018-09-26

Family

ID=56148123

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101558A AR108781A1 (es) 2016-06-07 2017-06-07 Aumento de la inmunogenicidad del péptido l2 de virus de papiloma humano (hpv)

Country Status (11)

Country Link
US (1) US10736954B2 (es)
EP (1) EP3463444A1 (es)
JP (1) JP6974358B2 (es)
CN (1) CN109310749B (es)
AR (1) AR108781A1 (es)
AU (1) AU2017276698B2 (es)
BR (1) BR112018075420A2 (es)
CA (1) CA3025855A1 (es)
RU (1) RU2743016C2 (es)
WO (1) WO2017211886A1 (es)
ZA (1) ZA201808246B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3078536A1 (fr) * 2018-03-05 2019-09-06 Peptinov Sas Composition vaccinale anti-pd-1
FR3078535B1 (fr) * 2018-03-05 2024-02-09 Peptinov Sas Composition vaccinale anti-pd-l1
EP3773708A2 (en) 2018-04-03 2021-02-17 Sanofi Antigenic epstein barr virus polypeptides
CN112512564A (zh) * 2018-04-03 2021-03-16 赛诺菲 铁蛋白蛋白
CN112423783A (zh) * 2018-05-30 2021-02-26 德国癌症研究中心 组合的预防性和治疗性疫苗
SG11202103851PA (en) 2018-10-18 2021-05-28 Deutsches Krebsforsch Dry pharmaceutical composition for inhalation
BR102019025802A2 (pt) 2019-12-05 2022-01-18 Instituto Butantan Processo de produção de uma composição imunológica de dna profilática e terapêutica contra hpv e cânceres associados ao vírus, proteína híbrida, vetor de expressão, composição imunológica e seus usos
KR102264535B1 (ko) * 2020-06-01 2021-06-14 (주)인테라 엔캡슐린 기반 백신 생산을 위한 재조합 발현 벡터 및 이의 제조방법
US20240084310A1 (en) * 2020-06-01 2024-03-14 Inthera Inc. Recombinant expression vector for production of encapsulin-based vaccine and method for manufacturing the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0105606D0 (en) 2001-03-07 2001-04-25 Cantab Pharmaceuticals Res Ltd Immunogens and vaccines and their preparation and use
EP1576967B1 (en) * 2004-03-18 2007-09-12 Institut Pasteur Recombinant protein, carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof, therapeutic uses thereof
US20100272753A1 (en) 2006-10-26 2010-10-28 The Johns Hopkins University Recombinant Adenovirus Vaccines
MX2010004850A (es) * 2007-11-02 2010-12-07 Univ Johns Hopkins Composiciones de peptidos de hpv de tipos multiples y metodos para tratamiento o prevencion de infeccion de virus de papiloma humano.
EP2199301A1 (en) * 2008-12-19 2010-06-23 DKFZ Deutsches Krebsforschungszentrum Immunogenic polypeptides comprising a scaffold polypeptide and a L2 polypeptide or fragment thereof
EP2576814A1 (en) 2010-06-02 2013-04-10 Deutsches Krebsforschungszentrum High-throughput method for determining the presence of papillomavirus-neutralizing antibodies in a sample

Also Published As

Publication number Publication date
JP2019525735A (ja) 2019-09-12
US10736954B2 (en) 2020-08-11
JP6974358B2 (ja) 2021-12-01
RU2743016C2 (ru) 2021-02-12
AU2017276698A1 (en) 2018-12-20
AU2017276698B2 (en) 2021-02-18
CN109310749A (zh) 2019-02-05
US20190125856A1 (en) 2019-05-02
CN109310749B (zh) 2022-09-23
CA3025855A1 (en) 2017-12-14
RU2018142386A3 (es) 2020-07-09
EP3463444A1 (en) 2019-04-10
WO2017211886A1 (en) 2017-12-14
ZA201808246B (en) 2022-10-26
BR112018075420A2 (pt) 2019-03-12
RU2018142386A (ru) 2020-07-09

Similar Documents

Publication Publication Date Title
AR108781A1 (es) Aumento de la inmunogenicidad del péptido l2 de virus de papiloma humano (hpv)
CO2017004838A2 (es) Vacunas terapéuticas contra el vph16
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
CO2018001623A2 (es) Vacunas terapéuticas contra el hpv18 y/o hpv16
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
JP2014534202A5 (es)
AR077396A2 (es) EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS
BR112015002131A8 (pt) Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante
NZ722700A (en) Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
PH12015500499A1 (en) Recombinant measles virus expressing chikungunya virus polypeptides and their applications
MX2020011299A (es) Vacunas mejoradas para el virus del papiloma humano y metodos para utilizarlas.
EA201591213A1 (ru) Вакцины против вируса гепатита b
AR101814A1 (es) Partícula de tipo virus flavivirus
EP2552490A4 (en) INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
CO2022003702A2 (es) Vacunas para vhb y métodos de tratamiento de vhb
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
PH12020550569A1 (en) A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
WO2018115509A3 (en) New flavivirus vaccine
AR095425A1 (es) Vacuna, uso y procedimiento para prevenir una infección por picornavirus
EA201890274A1 (ru) Векторная система из аденовируса 9 птиц (fadv-9) и связанные способы
MX2020006476A (es) Vacuna contra el virus de lassa.
JP2018501258A5 (es)
BR112017024283A2 (pt) vacinas contra a dengue
EA033242B1 (ru) Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением